Revisiting the X:BOT trial comparing ER naltrexone and buprenorphine.

More than four years after the X:BOT study showing that buprenorphine and extended‐release (ER) naltrexone (Vivitrol) were even in a head‐to‐head randomized trial, a new analysis "revisiting" the study data shows that the risk of overdose is greater with Vivitrol than with buprenorpine. The drugs performed equally at treatment retention at six months. [ABSTRACT FROM AUTHOR]